Anti-self/tumor T cell function can be improved by increasing TCR-peptide MHC (pMHC) affinity within physiological limits, but paradoxically further increases (
Michael Hebeisen, Lukas Baitsch, Danilo Presotto, Petra Baumgaertner, Pedro Romero, Olivier Michielin, Daniel E. Speiser, Nathalie Rufer
Functionality, TCR-αβ surface expression levels, and TCR/CD8 downregulation in CD8+ T cells engineered with self/tumor-specific TCR of incremental affinities.